

Product Data Sheet

Product Name: BIBF 1120-13C-d3

Cat. No.: GC46924

Chemical Properties

Cas. No. N/A

SMILES CN(C(CN1CCN([13C]([2H])([2H])[2H])CC1)=O)C(C=C2)=CC=C2N/C(C3=CC=CC=C3)=C4C(C=CC(C(OC)=O)=C5)=C5NC/4=O


Formula C30[13C]H30D3N5O4 M.Wt 543.7

Solubility DMSO: 25 mg/ml Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

BIBF 1120-¹³C-d₃ is intended for use as an internal standard for the quantification of BIBF 1120 by GC- or LC-MS. BIBF 1120 is an inhibitor of the receptor tyrosine kinases VEGFR, FGFR, and PDGFR (IC₅₀s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively).¹ It is selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

inhibit FLT3, LCK, LYN, and Src (IC_{50} s = 16-156 nM). BIBF 1120 inhibits growth factor-dependent proliferation of human umbilical vascular endothelial cells (HUVECs), human microvascular skin endothelial cells (HSMECs), human umbilical artery smooth muscle cells (HUASMCs), and bovine retinal pericytes (BRPs; EC_{50} s = 7-290 nM). *In vivo*, BIBF 1120 (100 mg/kg) reduces tumor microvessel density and the number of PDGFR β -expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model. It also inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model. Formulations containing BIBF 1120 have been used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer (NSCLC).

1. Hilberg, F., Roth, G.J., Krssak, M., et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. *Cancer Res.* 68(12):4774-4782 (2008)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA